SCHEMBL21330620

SCHEMBL21330620

C=CC(=O)N1CCCC(n2nc(-c3cnc(Oc4ccccc4)nc3)c3c(N)ncnc32)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 13/20 1.00
EGFR P00533 8/20 0.84
BMX P51813 4/20 0.84
ITK Q08881 4/20 0.84
TEC P42680 3/20 0.84
TXK P42681 2/20 0.84
LYN P07948 2/20 0.84
FGFR2 P21802 2/20 0.84
HCK P08631 2/20 0.84
SRC P12931 2/20 0.84
BLK P51451 2/20 0.84
RIPK2 O43353 1/20 0.84
NR1I2 O75469 1/20 0.84
SLC22A3 O75751 1/20 0.84
LATS1 O95835 1/20 0.84
NUDT14 O95848 1/20 0.84
ABL1 P00519 1/20 0.84
ERBB2 P04626 1/20 0.84
LCK P06239 1/20 0.84
FYN P06241 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20177228 1.00 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL2244870 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201642 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201859 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL2244865 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201641 0.91 BTK (1.00) BTKEGFRBMXITKTEC
SCHEMBL20177281 0.91 BTK (0.91) BTKEGFRBMXITKTEC
SCHEMBL21338838 0.91 BTK (0.91) BTKEGFRBMXITKTEC
SCHEMBL21330630 0.91 BTK (0.91) BTKEGFRBMXITKTEC
SCHEMBL21428758 0.89 BTK (0.95) BTKEGFRBMXITKTEC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543239-B1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF HANGZHOU HEALZEN THERAPEUTICS CO LTD (CN) 2024-11-13 EP disclosed
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2020-07-14 US disclosed
CN-108069974-B Selective Bruton tyrosine kinase inhibitor and application thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2019-12-10 CN disclosed
EP-3543239-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2019-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF BTK, BMX, KCNK10 BTK 1/4885EGFR 467/4885BMX 2/4885
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof BTK, SYK, LYN BTK 1/4885EGFR 189/4885BMX 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.